Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Enhertu approved in the US for gastric cancer
previously treated HER2-positive advanced gastric cancer AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. In the US, gastric cancer is most frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving beyond five years. 1,2 Approxim...
Source: investegate.co.uk